Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma (Q37038414)

17 August 2017

1 reference

title

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma (English)

1 reference

17 August 2017

0 references

0 references

Athanasios Dimopoulos

3

object named as

M A Dimopoulos

1 reference

International Myeloma Working Group

17 August 2017

35

object named as

International Myeloma Working Group

1 reference

17 August 2017

2

S V Rajkumar

1 reference

17 August 2017

32

B G Durie

1 reference

17 August 2017

A Palumbo

1

1 reference

17 August 2017

P G Richardson

4

1 reference

17 August 2017

J San Miguel

5

1 reference

17 August 2017

B Barlogie

6

1 reference

17 August 2017

J Harousseau

7

1 reference

17 August 2017

J A Zonder

8

1 reference

17 August 2017

M Cavo

9

1 reference

17 August 2017

M Zangari

10

1 reference

17 August 2017

M Attal

11

1 reference

17 August 2017

A Belch

12

1 reference

17 August 2017

S Knop

13

1 reference

17 August 2017

D Joshua

14

1 reference

17 August 2017

O Sezer

15

1 reference

17 August 2017

H Ludwig

16

1 reference

17 August 2017

D Vesole

17

1 reference

17 August 2017

J Bladé

18

1 reference

17 August 2017

R Kyle

19

1 reference

17 August 2017

J Westin

20

1 reference

17 August 2017

D Weber

21

1 reference

17 August 2017

S Bringhen

22

1 reference

17 August 2017

R Niesvizky

23

1 reference

17 August 2017

A Waage

24

1 reference

17 August 2017

M von Lilienfeld-Toal

25

1 reference

17 August 2017

S Lonial

26

1 reference

17 August 2017

G J Morgan

27

1 reference

17 August 2017

R Z Orlowski

28

1 reference

17 August 2017

K Shimizu

29

1 reference

17 August 2017

K C Anderson

30

1 reference

17 August 2017

M Boccadoro

31

1 reference

17 August 2017

P Sonneveld

33

1 reference

17 August 2017

M A Hussein

34

1 reference

17 August 2017

publication date

20 December 2007

1 reference

17 August 2017

1 reference

17 August 2017

volume

22

1 reference

17 August 2017

issue

2

1 reference

17 August 2017

page(s)

414-423

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2405062

17 August 2017

exact match

0 references

cites work

Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Malignancies, prothrombotic mutations, and the risk of venous thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Epidemiology and risk factors of venous thromboembolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

The thrombophilias: well-defined risk factors with uncertain therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Cancer and venous thromboembolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Venous Thromboembolism Associated With Long-Term Use of Central Venous Catheters in Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Normalization of hemoglobin level in patients with chronic kidney disease and anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

The blood coagulation mechanism in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Thalidomide as initial therapy for early-stage myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Thalidomide and dexamethasone for resistant multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Deep venous thrombosis and thalidomide therapy for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group Trial, HEM01-21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Thalidomide and hematopoietic-cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Thrombotic complications of myeloma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Gliosarcoma with intramedullary spinal metastases: a case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Positron emission tomography as an imaging biomarker

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

The relative role of PLCbeta and PI3Kgamma in platelet activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Venous thromboembolic risk and its prevention in hospitalized medical patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Clinical practice. Prophylaxis for thromboembolism in hospitalized medical patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Low-dose aspirin for the prevention of atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Utilisation and safety of low molecular weight heparins: prospective observational study in medical inpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Is impaired renal function a contraindication to the use of low-molecular-weight heparin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Imaging diagnosis of acute pulmonary embolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

7 January 2021

An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

7 January 2021

Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

7 January 2021

Cancer-associated thrombosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

7 January 2021

A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

7 January 2021

Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

7 January 2021

Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

7 January 2021

Thrombotic complications of central venous catheters in cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

7 January 2021

Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

7 January 2021

Correction of anemia with epoetin alfa in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

7 January 2021

The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

7 January 2021

The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide - vincristine - doxorubicin - methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

7 January 2021

Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

7 January 2021

Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

7 January 2021

Lenalidomide and venous thrombosis in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

7 January 2021

Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

7 January 2021

Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

7 January 2021

Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

7 January 2021

Risk of and prophylaxis for venous thromboembolism in hospital patients. Thromboembolic Risk Factors (THRIFT) Consensus Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

7 January 2021

Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

7 January 2021

Frequent asymptomatic pulmonary embolism in patients with deep venous thrombosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

7 January 2021

Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405062

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2405062

1 reference

Dimensions Publication ID

17 August 2017

1024288016

0 references

1 reference